Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IOPAMIDOL-370 IN PLASTIC CONTAINER vs RENOGRAFIN-76
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Iopamidol is a nonionic, low-osmolality radiocontrast agent that attenuates X-rays by blocking their passage, thereby enhancing the contrast of vascular structures and tissues during imaging. It does not have a specific molecular target but relies on its iodine content for radiopacity.
Radiopaque contrast agent that attenuates X-rays by absorbing them due to its high iodine content, allowing visualization of vascular structures and organs during radiographic procedures.
Intravascular administration for computed tomography (CT), angiocardiography, aortography, cerebral angiography, peripheral arteriography, venography, and intravenous urography.,Intrathecal administration for myelography (lumbar, thoracic, cervical, and total columnar myelography) and CT cisternography.
Intravascular use for computed tomography (CT) imaging of the head and body,Intravascular use for angiography and urography
Intravenous: 0.5-2 m L/kg (185-740 mg iodine/kg) as a single dose; repeated doses may be administered up to a total of 5 m L/kg (1850 mg iodine/kg) within a 24-hour period.
Intravenous administration of 50-100 m L (14.1-28.2 g iodine) as a single dose for angiography; dose varies by procedure and patient size.
Terminal half-life 1.5–2 hours in normal renal function; prolonged to 4–12 hours in severe renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life: 1–2 hours (normal renal function); prolonged to >20 hours in severe renal impairment (Cr Cl <10 m L/min)
e GFR <30 m L/min/1.73 m²: Use lowest possible dose and consider alternative imaging if possible. e GFR 30-59: No dose adjustment but ensure adequate hydration. e GFR ≥60: No adjustment needed.
e GFR <30 m L/min: contraindicated due to risk of contrast-induced nephropathy; e GFR 30-60: use lowest effective dose, ensure hydration; e GFR >60: no adjustment.
Serious adverse reactions, including fatal anaphylactic reactions, have been associated with the administration of iodinated contrast media. Emergency equipment and personnel trained in resuscitation should be readily available. Intrathecal administration may cause severe adverse reactions such as arachnoiditis, meningitis, and neurologic injury.
Iopamidol is a nonionic iodinated contrast agent. Limited data in pregnant women; animal studies have not shown teratogenic effects. First trimester: theoretical risk of fetal hypothyroidism if high doses administered, but no evidence of congenital malformations. Second and third trimesters: minimal risk; iodinated contrast agents cross the placenta and may transiently suppress fetal thyroid function. Overexposure may cause neonatal hypothyroidism, but single diagnostic doses are considered low risk.
RENOGRAFIN-76 is an iodinated contrast agent. Teratogenic risk: a) First trimester: No known increased risk of major malformations from clinical data; however, theoretical risk from free iodide causing fetal thyroid suppression with high doses or prolonged exposure. b) Second and third trimesters: Potential fetal hypothyroidism from iodide exposure; risk decreases with gestational age. Neonatal thyroid function screening recommended after in utero exposure.
Pre-warm Iopamidol-370 to 37°C to reduce viscosity and decrease injection pressure. Ensure adequate hydration (e.g., 1-3 m L/kg IV fluids) before and after administration to prevent contrast-induced nephropathy, especially in patients with e GFR < 30 m L/min. Screen for metformin use; discontinue 48 hours prior and hold for 48 hours post-procedure unless e GFR is normal. Have emergency equipment ready for anaphylactoid reactions: epinephrine, diphenhydramine, corticosteroids. For patients with pheochromocytoma, pre-treat with alpha-blockade (e.g., phenoxybenzamine) to prevent hypertensive crisis.
No interactions on record
No interactions on record
IOPAMIDOL-370 IN PLASTIC CONTAINER and RENOGRAFIN-76 are distinct pharmacological agents. IOPAMIDOL-370 IN PLASTIC CONTAINER belongs to the Radiocontrast Agent class and is primarily used for Intravascular administration for computed tomography (CT), angiocardiography, aortography, cerebral angiography, peripheral arteriography, venography, and intravenous urography.Intrathecal administration for myelography (lumbar, thoracic, cervical, and total columnar myelography) and CT cisternography.. RENOGRAFIN-76 belongs to the Radiocontrast Agent class and is primarily used for Intravascular use for computed tomography (CT) imaging of the head and bodyIntravascular use for angiography and urography. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. IOPAMIDOL-370 IN PLASTIC CONTAINER carries a safety status of Category C, whereas RENOGRAFIN-76 safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Iopamidol is not metabolized; it is excreted unchanged by the kidneys via glomerular filtration.
Not metabolized; excreted unchanged via glomerular filtration.
Renal: >90% unchanged by glomerular filtration within 24–48 hours; biliary/fecal: <2%.
Renal: >95% unchanged via glomerular filtration; biliary/fecal: negligible (<5%)
<10% (minimal binding to plasma proteins).
Low (<10%), primarily to albumin; negligible binding to other proteins
0.2–0.3 L/kg (mostly extracellular fluid, not entering cells or red blood cells).
0.2–0.3 L/kg; confined to extracellular fluid, minimal intracellular penetration
Intravenous: 100% (only IV/intra-arterial use; no oral bioavailability as not absorbed).
Oral: <1% (due to poor absorption and first-pass effect); Intravenous: 100%
No specific dose adjustment required for hepatic impairment based on Child-Pugh class. Use caution in severe hepatic impairment due to potential comorbidity.
No specific adjustments for hepatic impairment; use caution in severe hepatic dysfunction due to potential coagulation abnormalities.
Intravenous: 1-2 m L/kg (370-740 mg iodine/kg) as a single dose; maximum total dose 5 m L/kg (1850 mg iodine/kg) in 24 hours.
0.5-2.0 m L/kg (141-564 mg iodine/kg) intravenously, not to exceed adult dose; individualize based on age, weight, and procedure.
No specific dose adjustment solely based on age. Assess renal function (e GFR) and adjust accordingly. Ensure adequate hydration before and after administration.
Use lowest effective dose; ensure adequate hydration; monitor renal function as age-related decline increases risk of nephrotoxicity.
Not for intrathecal use; severe adverse reactions including convulsions and death have occurred following inadvertent intrathecal administration.
Risk of serious hypersensitivity reactions (anaphylaxis), contrast-induced nephropathy (especially in patients with pre-existing renal impairment, diabetes, or dehydration), thyroid dysfunction (in patients with hyperthyroidism or thyroid tumors), and neurological disturbances (e.g., seizures, confusion) with intrathecal use. Caution in patients with pheochromocytoma, sickle cell disease, or concomitant use of nephrotoxic drugs.
Absolute: Known hypersensitivity to iopamidol or any component, history of anaphylaxis to iodinated contrast media, and intrathecal use in patients with a history of seizures or myelography with suspected spinal block. Relative: Severe renal impairment (e.g., e GFR <30 m L/min), severe hepatic impairment, and concurrent administration of metformin (risk of lactic acidosis).
No specific food interactions with Iopamidol-370. However, patients should maintain adequate hydration; avoid alcohol and caffeinated beverages 24 hours prior to procedure as they may contribute to dehydration.
Iopamidol is excreted into breast milk in small amounts. The M/P ratio is approximately 0.1. Based on the limited data, it is considered compatible with breastfeeding. The American College of Radiology recommends that no special precautions are necessary, and breastfeeding can continue without interruption after contrast administration.
Excreted into breast milk in small amounts (<1% of maternal dose). M/P ratio not established. Oral bioavailability in infant negligible. American College of Radiology considers contrast administration compatible with breastfeeding; no need to interrupt breastfeeding. Advise discarding milk for 24 hours if mother is concerned.
No dose adjustment required for single diagnostic use. Pregnancy does not significantly alter the pharmacokinetics of iopamidol; however, total body water increase may slightly dilute contrast agent, but not to a clinically significant degree. Standard dosing based on body weight is appropriate.
No specific dose adjustments required based on pregnancy pharmacokinetics. Use lowest necessary dose due to increased vascular volume and glomerular filtration rate in pregnancy. Ensure adequate hydration before and after. Dose based on procedure and maternal weight; no adjustment for gestational age.
Inform your doctor if you have a history of allergic reactions to contrast agents, iodine, or seafood.,Drink plenty of fluids before and after the procedure unless told otherwise.,Report any symptoms such as hives, itching, difficulty breathing, or swelling of the face/throat immediately.,If you take metformin for diabetes, your doctor may ask you to stop it for 48 hours before and after the test.,You may feel a warm sensation or metallic taste during injection; this is normal and temporary.
This contrast agent is used to enhance imaging of blood vessels, organs, and other structures.,You may experience a warm sensation, metallic taste, or flushing during injection; these are usually temporary.,Inform your healthcare provider if you have allergies (especially to iodine or contrast media), asthma, kidney disease, diabetes, or are pregnant or breastfeeding.,Drink plenty of fluids before and after the procedure to help protect your kidneys.,Report any symptoms like hives, difficulty breathing, or swelling of face/throat immediately to medical staff.